Department of Health and Human Services, through National Institutes of Health, awarded Astrocyte Pharmaceuticals Inc. of Cambridge, MA $2,999,688 under the STTR program (Phase I), with work starting 2025-06-12 and running to 2027-05-31. It is one of 2 SBIR and STTR awards Astrocyte Pharmaceuticals Inc. received in the last two years, $3,399,368 in all. Each figure links to the federal record.
The award
| Recipient | Astrocyte Pharmaceuticals Inc. (Cambridge, MA) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase I |
| Amount obligated | $2,999,688 |
| Period of performance starts | 2025-06-12 |
| Period of performance ends | 2027-05-31 |
| Award number | R44NS137896 (grant, CFDA 93.853) |
| Assistance listing | 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Place of performance | Cambridge, Middlesex County, MA |
| Signed | 2025-06-10 |
| Recipient registry id (UEI) | ZEP1G3FGYUP3 |
Want the whole picture on Astrocyte Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Astrocyte Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Astrocyte Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Preclinical efficacy and safety evaluation of oral AST-004 for moderate traumatic brain injury (tbi) - project summary traumatic brain injuries (tbi), including concussions, are an area of significant unmet need with no
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-08-24 | Continuation | 001 | $1,499,802 |
| 2026-08-11 | Revision | 000 | $0 |
| 2025-06-10 | New | 000 | $1,499,886 |
Preclinical efficacy and safety evaluation of oral AST-004 for moderate traumatic brain injury (tbi) - project summary traumatic brain injuries (tbi), including concussions, are an area of significant unmet need with no approved therapeutics and a national burden of ~$77 billion annually. Tbi is the global leading cause of post-injury death and disability, and over 2 million americans sustain a tbi each year. Approximately 1 out of every 60 people in the u.s. Lives with a tbi-related disability. The tremendous incidence and long-term consequences of tbi highlight the considerable epidemic at hand, and the need for neuroprotective treatments. Astrocyte pharmaceuticals inc. Is developing the proprietary small molecule pharmaceutical agent AST-004 for acute administration to tbi patients that will dramatically improve the survival of neurons, affected brain tissue, and the long-term neurological deficits that have been linked to tbi. The proprietary approach at astrocyte pharmaceuticals differs significantly from historical neuroprotective attempts in that IT focuses on a non- neuronal cell type, the astrocyte, which has only recently received broader attention as an important cellular target for successful therapeutic research. AST-004 enhances and maintains astrocyte mitochondrial function and improves multiple healing mechanisms including protection against edema, glutamate exc ...
From the federal award record.
Other SBIR and STTR awards to Astrocyte Pharmaceuticals Inc.
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2026-07-15 | Department of Health and Human Services | STTR Phase I | $399,680 | Preclinical efficacy of AST-004 as a treatment for substance use disorder - project summar (record) |
Every other federal award to Astrocyte Pharmaceuticals Inc. on record
The federal register lists 3 other awards to the same registry id (UEI ZEP1G3FGYUP3), $3,965,418 in all, from 1 agency.
| Starts | Agency | Amount | Award |
|---|---|---|---|
| 2018-09-30 | National Institutes of Health | $297,946 | Astrocyte activation by small-molecule ADORA3 agonists: A novel therapy for alzheimer's disease (R41AG062163) |
| 2015-09-30 | National Institutes of Health | $2,995,813 | Preclinical development of AST-004 for astrocyte-mediated treatment of tbi. (R44NS093756) |
| 2015-09-30 | National Institutes of Health | $671,659 | Astrocyte activation by small molecule P2Y1 agonists for treatment of tbi (R41NS093756) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Astrocyte Pharmaceuticals Inc.Look up Astrocyte Pharmaceuticals Inc. first. Finding the company and seeing how much is on record uses no credits.
Look up Astrocyte Pharmaceuticals Inc.Where this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.